US20080161573A1 - Process for the preparation of imiquimod and intermediates thereof - Google Patents

Process for the preparation of imiquimod and intermediates thereof Download PDF

Info

Publication number
US20080161573A1
US20080161573A1 US11/872,895 US87289507A US2008161573A1 US 20080161573 A1 US20080161573 A1 US 20080161573A1 US 87289507 A US87289507 A US 87289507A US 2008161573 A1 US2008161573 A1 US 2008161573A1
Authority
US
United States
Prior art keywords
ethyl ester
isobutyl
acid ethyl
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/872,895
Inventor
Lino Colombo
Enrico Mariotti
Pietro Allegrini
Graziano Castaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dipharma SpA
Original Assignee
Dipharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dipharma SpA filed Critical Dipharma SpA
Priority to US11/872,895 priority Critical patent/US20080161573A1/en
Assigned to DIPHARMA S.P.A. reassignment DIPHARMA S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLEGRINI, PIETRO, CASTALDI, GRAZIANO, COLOMBO, LINO, MARIOTTI, ENRICO
Publication of US20080161573A1 publication Critical patent/US20080161573A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel intermediates useful in the synthesis of Imiquimod, and the use of said intermediates in a process for its preparation.
  • Imiquimod namely 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (A)
  • A is an antiviral, immunomodulating medicament, disclosed in U.S. Pat. No. 4,689,338.
  • the synthetic scheme 1 involves, inter alia, the condensation of a quinoline (5), having amino groups at the 3- and 4-positions, with a trialkyl-orthoester to afford the 1H-imidazo[4,5-c]quinoline derivative (6), followed by introduction of a chlorine substituent at the 4-position, previous oxidation of the nitrogen at the 5-position and reaction of the resulting N-oxide (7) with a chlorinated agent. The chlorine atom at the 4-position is then substituted with an amino group by treatment with ammonia. It is apparent from the scheme herein reported that this process is time-consuming and complex. Moreover, the synthesis makes use of nitro derivatives (2), (3) and (4), in addition to the N-oxide (7), which are known to give uncontrollable reactions potentially hazardous to the operators.
  • the synthetic Scheme 2 requires, inter alia, the nitration of a compound (9); the introduction of two chlorine atoms at the 2 and 4 positions of a compound (10) to obtain 2,4-dichloro-3-nitroquinoline (11); the amination at the 4 position to give a compound (12); the reduction of the nitro group at the 3 position; the condensation of the quinoline (13) having amino groups at the 3 and 4 positions with a trialkyl-orthoester to afford 4-chloro-1H-imidazo[4,5-c]quinoline (I); and finally the substitution of the chlorine atom at the 4 position with an amino group to give Imiquimod.
  • the process involves the preparation of intermediate (15) which requires, inter alia, the use of nitric acid and sodium azide, products known to be dangerous. Furthermore, said intermediate, like other intermediates useful for the synthesis of Imiquimod, is characterized by the simultaneous presence of a nitro group and a tetrazole ring. These functionalities are known to give the molecule high decomposition energy, which involves risks in handling it. Moreover, these synthetic processes also are long and cumbersome.
  • a first object of the invention is a process for the preparation of 1-isobutyl-4-chloro-1H-imidazo[4,5-c]quinoline, of formula (I)
  • a suitable chlorinating agent is, for example, thionyl chloride, sulforyl chloride, phosphorous trichloride, phosphorous pentachloride, phosphorous oxychloride, phosgene and triphosgene, in particular phosphorous oxychloride.
  • the reaction can optionally be carried out in an organic solvent, typically, a chlorinated solvent, such as dichloromethane, dichloroethane, tetrachloroethylene, chlorobenzene or dichlorobenzene; an ester solvent, such as ethyl acetate, isopropyl acetate or butyl acetate; a hydrocarbon solvent, such as cyclohexane, toluene, xylene or mixtures of xylenes; or a mixture of said organic solvents.
  • the chlorinating agent can be used as solvent as well.
  • the reaction can be carried out at a temperature ranging from about 0° C. to the reflux temperature of the reaction mixture, preferably from about 40° C. to the reflux temperature.
  • the compound of formula (II) is a novel compound and is a further object of the invention, as well as its tautomeric forms, such as the tautomer of formula (IIa),
  • a compound of formula (II) can be obtained by intramolecular aromatic nucleophilic substitution between the NH 2 group and the X group in a compound of formula (III)
  • the leaving group X is preferably a halogen atom, in particular chlorine, bromine or iodine, a nitro group or a reactive hydroxy group, in particular —OSO 2 R wherein R is a C 1 -C 10 alkyl group, a perchloro or perfluoro C 1 -C 10 alkyl group, or an optionally substituted aromatic group, for example phenyl.
  • Preferred examples of X as reactive hydroxy group are mesyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, p-nitrobenzenesulfonyloxy, trifluoromethylsulfonyloxy and perfluorobutylsulfonyloxy.
  • Particularly preferred meanings of X are bromine and chlorine.
  • the reaction is preferably carried out in the presence of catalysts, typically based on transition metals, or complexes thereof, such as Pd, Pt and Cu.
  • catalysts typically based on transition metals, or complexes thereof, such as Pd, Pt and Cu.
  • the Cu based catalysts particularly cuprous halides such as CuCl, CuBr and CuI, are preferred, the latter being more preferred.
  • Palladium complexes are for example complexes with arylphosphines or aryl-alkylphosphines.
  • the catalyst can be used in the presence of ligands. In the case of copper based catalysts, amino ligands can be used. Diamines, in particular N,N′-dimethylethylenediamine, are preferred.
  • a compound of formula (III), and all the possible isomers thereof, is a novel compound and is a further object of the invention.
  • a compound of formula (III) can be obtained by reaction of a compound of formula (IV) with ammonia
  • X is as defined above and Y is a reactive carboxylic group.
  • reactive carboxylic group Y is a —CORa group, wherein Ra is a halogen atom, preferably chlorine, or a —COORb group, wherein Rb is a straight or branched C 1 -C 10 alkyl group, optionally substituted, or an optionally substituted aryl group, for example phenyl.
  • An Y group can also be a group obtained by activation of the corresponding free carboxylic acid derivative, by treatment with activating agents, for example carbodiimides, such as dicyclohexyl carbodiimide or ethyl dimethylpropyl carbodiimide, carbonyl diimidazole or chloroformates, such as methyl chloroformate, ethyl chloroformate or isobutylchloroformate.
  • activating agents for example carbodiimides, such as dicyclohexyl carbodiimide or ethyl dimethylpropyl carbodiimide, carbonyl diimidazole or chloroformates, such as methyl chloroformate, ethyl chloroformate or isobutylchloroformate.
  • activating agents for example carbodiimides, such as dicyclohexyl carbodiimide or ethyl dimethylpropyl carbodiimide, carbonyl diimi
  • reaction of a compound of formula (IV) with ammonia can be carried out according to known methods, for example as illustrated in the Experimental Section.
  • a compound of formula (IV) is a novel compound and is a further object of the invention.
  • Preferred examples of compounds of formula (IV) are:
  • a compound of formula (IV) can be obtained according to known methods from the corresponding free carboxylic derivative (V)
  • a compound of formula (IV) in which Y is a —CORa group, wherein Ra is a halogen atom can be obtained by reaction of a compound of formula (V) with a halogenating agent, such as SOCl 2 , SO 2 Cl 2 , PCl 3 , POCl 3 , PCl 5 , phosgene or triphosgene, according to known methods.
  • a compound of formula (IV) wherein Y is a —COORb group is also a compound of formula (VI) as herein defined and can be obtained following the synthesis described herein.
  • a compound of formula (V) can be obtained according to the following synthetic Scheme 4, or modifications thereof, by means of known chemical reactions.
  • Rb and X are as defined above;
  • W is a halogen atom, such as chlorine or bromine; and the halogenating agent is for example N-chlorosuccinimide or N-bromosuccinimide.
  • the compounds of formulae (VI), (VII), (VIII) and (IX) above, and the possible isomers thereof, are novel compounds and are a further object of the invention.
  • Preferred compounds of formulae (VI), (VII), (VIII) and (IX) are those in which Rb is C 1 -C 6 alkyl, in particular methyl, ethyl or propyl; W is bromine; and X is bromine or chlorine.
  • the invention further provides the use of a compound of formula (II) in a process for the preparation of Imiquimod, more specifically, said process comprising the substitution of the chlorine atom at the 4 position in a compound of formula (I)
  • substitution of the chlorine atom at the 4 position in a compound of formula (I) with an amino group can be carried out according to known methods, for example as described in U.S. Pat. No. 4,689,338 column 6 or in U.S. Pat. No. 4,988,815 column 4.
  • the product is crystallized from isopropyl ether thereby obtaining 5.3 g of 3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester as a white solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel intermediates useful for the preparation of Imiquimod and a process for the preparation of Imiquimod with the intermediates.

Description

    FIELD OF THE INVENTION
  • The present invention relates to novel intermediates useful in the synthesis of Imiquimod, and the use of said intermediates in a process for its preparation.
  • Imiquimod, namely 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (A), is an antiviral, immunomodulating medicament, disclosed in U.S. Pat. No. 4,689,338.
  • Figure US20080161573A1-20080703-C00001
    • TECHNOLOGICAL BACKGROUND
  • A number of synthetic methods for the preparation of Imiquimod are known, some of which use the corresponding 4-chloro-1H-imidazo[4,5-c]quinoline (I) as an intermediate.
  • One of these processes is disclosed in U.S. Pat. No. 4,689,338 and can be represented according to the following Scheme 1:
  • Figure US20080161573A1-20080703-C00002
  • The synthetic scheme 1 involves, inter alia, the condensation of a quinoline (5), having amino groups at the 3- and 4-positions, with a trialkyl-orthoester to afford the 1H-imidazo[4,5-c]quinoline derivative (6), followed by introduction of a chlorine substituent at the 4-position, previous oxidation of the nitrogen at the 5-position and reaction of the resulting N-oxide (7) with a chlorinated agent. The chlorine atom at the 4-position is then substituted with an amino group by treatment with ammonia. It is apparent from the scheme herein reported that this process is time-consuming and complex. Moreover, the synthesis makes use of nitro derivatives (2), (3) and (4), in addition to the N-oxide (7), which are known to give uncontrollable reactions potentially hazardous to the operators.
  • The synthesis of Imiquimod via the corresponding 4-chloro-1H-imidazo[4,5-c]quinoline (I) is also disclosed in U.S. Pat. No. 4,988,815, according to the following Scheme 2:
  • Figure US20080161573A1-20080703-C00003
  • The synthetic Scheme 2 requires, inter alia, the nitration of a compound (9); the introduction of two chlorine atoms at the 2 and 4 positions of a compound (10) to obtain 2,4-dichloro-3-nitroquinoline (11); the amination at the 4 position to give a compound (12); the reduction of the nitro group at the 3 position; the condensation of the quinoline (13) having amino groups at the 3 and 4 positions with a trialkyl-orthoester to afford 4-chloro-1H-imidazo[4,5-c]quinoline (I); and finally the substitution of the chlorine atom at the 4 position with an amino group to give Imiquimod. In this case also the process is time-consuming and complex, and the use of nitro derivatives (10), (11) and (12) involves the already mentioned risks. Alternative synthetic routes for the preparation of Imiquimod are reported in WO 97/48704. One of these is represented in the following Scheme 3:
  • Figure US20080161573A1-20080703-C00004
  • The process involves the preparation of intermediate (15) which requires, inter alia, the use of nitric acid and sodium azide, products known to be dangerous. Furthermore, said intermediate, like other intermediates useful for the synthesis of Imiquimod, is characterized by the simultaneous presence of a nitro group and a tetrazole ring. These functionalities are known to give the molecule high decomposition energy, which involves risks in handling it. Moreover, these synthetic processes also are long and cumbersome.
  • There is therefore the need for an alternative process for the preparation of Imiquimod, which is well suited to the industrial production.
  • It has been found that intermediate (I), described above, can be conveniently obtained with a preparation procedure which is simpler, safer and makes use of commercially available intermediates. The advantages of the novel process for the preparation of Imiquimod, which involve no potentially hazardous intermediates, will be further evidenced in the following.
    • DETAILED DISCLOSURE OF THE INVENTION
  • A first object of the invention is a process for the preparation of 1-isobutyl-4-chloro-1H-imidazo[4,5-c]quinoline, of formula (I)
  • Figure US20080161573A1-20080703-C00005
  • comprising the reaction of 1-isobutyl-1,5-dihydro-imidazo[4,5-a]quinoline-4-one, of formula (II)
  • Figure US20080161573A1-20080703-C00006
  • with a chlorinating agent.
  • A suitable chlorinating agent is, for example, thionyl chloride, sulforyl chloride, phosphorous trichloride, phosphorous pentachloride, phosphorous oxychloride, phosgene and triphosgene, in particular phosphorous oxychloride. The reaction can optionally be carried out in an organic solvent, typically, a chlorinated solvent, such as dichloromethane, dichloroethane, tetrachloroethylene, chlorobenzene or dichlorobenzene; an ester solvent, such as ethyl acetate, isopropyl acetate or butyl acetate; a hydrocarbon solvent, such as cyclohexane, toluene, xylene or mixtures of xylenes; or a mixture of said organic solvents. The chlorinating agent can be used as solvent as well. The reaction can be carried out at a temperature ranging from about 0° C. to the reflux temperature of the reaction mixture, preferably from about 40° C. to the reflux temperature.
  • The compound of formula (II) is a novel compound and is a further object of the invention, as well as its tautomeric forms, such as the tautomer of formula (IIa),
  • Figure US20080161573A1-20080703-C00007
  • and all the possible isomers thereof.
  • A compound of formula (II) can be obtained by intramolecular aromatic nucleophilic substitution between the NH2 group and the X group in a compound of formula (III)
  • Figure US20080161573A1-20080703-C00008
  • wherein X is a leaving group.
  • The leaving group X is preferably a halogen atom, in particular chlorine, bromine or iodine, a nitro group or a reactive hydroxy group, in particular —OSO2R wherein R is a C1-C10 alkyl group, a perchloro or perfluoro C1-C10 alkyl group, or an optionally substituted aromatic group, for example phenyl. Preferred examples of X as reactive hydroxy group are mesyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, p-nitrobenzenesulfonyloxy, trifluoromethylsulfonyloxy and perfluorobutylsulfonyloxy. Particularly preferred meanings of X are bromine and chlorine.
  • The reaction is preferably carried out in the presence of catalysts, typically based on transition metals, or complexes thereof, such as Pd, Pt and Cu. The Cu based catalysts, particularly cuprous halides such as CuCl, CuBr and CuI, are preferred, the latter being more preferred. Palladium complexes are for example complexes with arylphosphines or aryl-alkylphosphines. The catalyst can be used in the presence of ligands. In the case of copper based catalysts, amino ligands can be used. Diamines, in particular N,N′-dimethylethylenediamine, are preferred.
  • A compound of formula (III), and all the possible isomers thereof, is a novel compound and is a further object of the invention.
  • Specific examples of compounds of formula (III) are:
    • 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxamide; and
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxamide.
  • A compound of formula (III) can be obtained by reaction of a compound of formula (IV) with ammonia
  • Figure US20080161573A1-20080703-C00009
  • wherein X is as defined above and Y is a reactive carboxylic group.
  • An example of reactive carboxylic group Y is a —CORa group, wherein Ra is a halogen atom, preferably chlorine, or a —COORb group, wherein Rb is a straight or branched C1-C10 alkyl group, optionally substituted, or an optionally substituted aryl group, for example phenyl. An Y group can also be a group obtained by activation of the corresponding free carboxylic acid derivative, by treatment with activating agents, for example carbodiimides, such as dicyclohexyl carbodiimide or ethyl dimethylpropyl carbodiimide, carbonyl diimidazole or chloroformates, such as methyl chloroformate, ethyl chloroformate or isobutylchloroformate. Preferably Y is a —CORa or —COORb group, wherein Rb is preferably C1-C6 alkyl, in particular methyl, ethyl or propyl.
  • The reaction of a compound of formula (IV) with ammonia can be carried out according to known methods, for example as illustrated in the Experimental Section.
  • A compound of formula (IV) is a novel compound and is a further object of the invention.
  • Preferred examples of compounds of formula (IV) are:
    • 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-chlorocarbonyl;
    • 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester; and
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester.
  • A compound of formula (IV) can be obtained according to known methods from the corresponding free carboxylic derivative (V)
  • Figure US20080161573A1-20080703-C00010
  • wherein X is as defined above.
  • For example, a compound of formula (IV) in which Y is a —CORa group, wherein Ra is a halogen atom, can be obtained by reaction of a compound of formula (V) with a halogenating agent, such as SOCl2, SO2Cl2, PCl3, POCl3, PCl5, phosgene or triphosgene, according to known methods. A compound of formula (IV) wherein Y is a —COORb group is also a compound of formula (VI) as herein defined and can be obtained following the synthesis described herein.
  • A compound of formula (V) can be obtained according to the following synthetic Scheme 4, or modifications thereof, by means of known chemical reactions.
  • Figure US20080161573A1-20080703-C00011
  • wherein Rb and X are as defined above; W is a halogen atom, such as chlorine or bromine; and the halogenating agent is for example N-chlorosuccinimide or N-bromosuccinimide.
  • An example of the reactions sequence reported above is illustrated in the Experimental Section. This sequence is preferably carried out using the specific halogenating agents herein indicated and alkyl, in particular ethyl, esters of the compounds of formulae (VI), (VII), (VIII) and (IX). However, this procedure can also be carried out using similar, known methods.
  • The compounds of formulae (VI), (VII), (VIII) and (IX) above, and the possible isomers thereof, are novel compounds and are a further object of the invention. Preferred compounds of formulae (VI), (VII), (VIII) and (IX) are those in which Rb is C1-C6 alkyl, in particular methyl, ethyl or propyl; W is bromine; and X is bromine or chlorine.
  • Specific examples of compounds of formula (IX) are:
    • 3-(2-chloro-phenyl)-2-formylamino-acrylic acid ethyl ester; and
    • 3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester.
  • Specific examples of compounds of formula (VIII) are:
    • 3-bromo-3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester;
    • 3-bromo-3-(2-chloro-phenyl)-2-formylamino-acrylic acid ethyl ester;
    • 3-chloro-3-(2-bromophenyl)-2-formylamino-acrylic acid ethyl ester; and
    • 3-chloro-3-(2-chlorophenyl)-2-formylamino-acrylic acid ethyl ester.
  • Specific examples of compounds of formula (VII) are
    • 3-bromo-3-(2-bromophenyl)-2-isocyano-acrylic ethyl acid ester;
    • 3-bromo-3-(2-chlorophenyl)-2-isocyano-acrylic acid ethyl ester;
    • 3-chloro-3-(2-bromophenyl)-2-isocyano-acrylic acid ethyl ester; and
    • 3-chloro-3-(2-chlorophenyl)-2-isocyano-acrylic acid ethyl ester.
  • Specific examples of compounds of formula (VI) are:
    • 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester; and
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester.
  • The invention further provides the use of a compound of formula (II) in a process for the preparation of Imiquimod, more specifically, said process comprising the substitution of the chlorine atom at the 4 position in a compound of formula (I)
  • Figure US20080161573A1-20080703-C00012
  • with an amino group, wherein the compound of formula (I) is obtained by treatment of a compound of formula (II) with a halogenating agent according to the process herein described.
  • The substitution of the chlorine atom at the 4 position in a compound of formula (I) with an amino group, can be carried out according to known methods, for example as described in U.S. Pat. No. 4,689,338 column 6 or in U.S. Pat. No. 4,988,815 column 4.
  • The following examples further illustrate the invention.
  • The 1H-NMR spectra were recorded with a Bruker 400 MHz apparatus.
    • EXAMPLE 1 3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester; (IX)
  • A 1M solution of ethyl isocyanoacetate (7.5 ml; 68.6 mM) and 2-bromobenzaldehyde (7.93 ml; 68.6 mM) in anhydrous tetrahydrofuran (THF), is added drop by drop to a suspension of NaH (55-60% in paraffin) (3.60 g; 82.32 mM) in 67 ml of anhydrous THF, the latter on an ice-salt bath (brine). The reaction is carried out at room temperature and is completed in about one hour. The reaction is quenched at 0° C. with a 10% acetic acid solution (67 ml), the organic phase is completely evaporated off and the residue is extracted with CH2Cl2. The combined organic phases are washed once with water, dried over Na2SO4, filtered and evaporated under reduced pressure. A crude of 14.5 g (dark brownish oil) is obtained.
  • The product is crystallized from isopropyl ether thereby obtaining 5.3 g of 3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester as a white solid.
  • 1H-NMR (CDCl3): δ 1.42 (t, 3H); 4.33-4.44 (q, 2H); 7.07-7.26 (m, 2H); 7.32-7.58 (m, 3H); 7.62-7.69 (bd, 1H); 8.12-8.23 (m, 1H).
  • According to the same procedure, the following compound can be obtained:
    • 3-(2-chloro-phenyl)-2-formylamino-acrylic acid ethyl ester.
    EXAMPLE 2 3-bromo-3-(2-bromophenyl)-2-formylamino-acrylic acid ethyl ester; (VIII)
  • A 0.4 M solution of 3-(2-bromo-phenyl)-2-formylamino-acrylic acid ethyl ester (5.3 g; 17.8 mM) in anhydrous CH2Cl2, at 0° C., is added with N-bromosuccinimide (3.48 g; 19.6 mM). The mixture is left to slowly warm to room temperature. The reaction is completed in about 5 hours 30 min. The equivalent amount of triethylamine is added drop by drop; after 30 minutes the mixture is washed with a NaHCO3 saturated solution and then with a NaCl saturated solution. The organic phase is dried over Na2SO4, the solid is filtered off and the clear solution is evaporated under reduced pressure to a residue. The crude (brownish oil) is purified by flash chromatography, using a 6:4 v/v mixture of hexane and ethyl acetate as eluent, thereby obtaining 2.68 g of 3-bromo-3-(2-bromophenyl)-2-formylamino-acrylic acid ethyl ester (white-pale yellow solid). (Yield: 40%).
  • 1H-NMR (DMSO): δ 0.75 (t, 3H); 3.82 (2q, 2H); 7.30-7.36 (m, 2H); 7.43 (t, 1H); 7.67-7.72 (m, 1H); 8.19 (s, 1H); 10.2 (bs, 1H).
  • According to the same procedure, the following compounds can be obtained:
    • 3-bromo-3-(2-chlorophenyl)-2-formylamino-acrylic acid ethyl ester;
    • 3-chloro-3-(2-bromophenyl)-2-formylamino-acrylic acid ethyl ester; and
    • 3-chloro-3-(2-chlorophenyl)-2-formylamino-acrylic acid ethyl ester.
    EXAMPLE 3 3-Bromo-3-(2-bromophenyl)-2-isocyano acrylic acid ethyl ester; (VII)
  • A 1M solution of 3-bromo-3-(2-bromophenyl)-2-formylamino-acrylic acid ethyl ester (2.68 g; 7.11 mM) and triethylamine (2.67 ml; 19.19 mM) in anhydrous CH2Cl2 is added drop by drop with POCl3 (730 μl, 7.82 mM), under vigorous stirring at −20° C. The mixture is left to slowly warm to room temperature. The reaction is completed after about one hour 15 min. Quenching is carried out with a 20% solution K2CO3 solution (7.1 ml). The organic phase is washed with water, dried over Na2SO4, filtered and evaporated under reduced pressure, thereby obtaining 2.55 g of 3-bromo-3-(2-bromophenyl)-2-isocyano-acrylic acid ethyl ester, as crude product (quantitative yield), which is used for the subsequent reaction.
  • 1H-NMR (CDCl3) δ 1.07 (t, 3H); 4.11 (m, 2H); 7.23-7.27 (m, 1H); 7.29-7.31 (m, 1H); 7.40 (m, 1H); 7.64 (dd, 1H J1=8.0 J2=0.8 Hz).
  • According to the same procedure, the following compounds can be obtained:
    • 3-bromo-3-(2-chlorophenyl)-2-isocyano-acrylic acid ethyl ester;
    • 3-chloro-3-(2-bromophenyl)-2-isocyano-acrylic acid ethyl ester; and
    • 3-chloro-3-(2-chlorophenyl)-2-isocyano-acrylic acid ethyl ester.
    EXAMPLE 4 5-(2-Bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester; (VI)
  • A 0.5 M solution of 3-bromo-3-(2-bromophenyl)-2-isocyano-acrylic acid ethyl ester (2.55 g; 7.11 mM) and triethylamine (990 μl; 7.11 mM) in dimethylformamide (DMF) is added drop by drop at room temperature with isobutylamine (850 μl; 8.53 mM). The reaction mixture is kept at room temperature until complete reaction, then is quenched with a NaHCO3 saturated solution, extracted with ethyl acetate, washed with water, dried over Na2SO4, and evaporated under reduced pressure. The crude is purified by flash chromatography, eluting with ethyl acetate, to obtain 1.77 g of 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester. (Yield: 71%).
  • 1H-NMR (CDCl3) δ 0.80 (d, 3H); 0.84 (d, 3H); 1.21 (t, 3H); 1.83 (m, 1H); 3.47 (q, 1H); 3.65 (q, 1H); 4.23 (m, 2H); 7.29-7.39 (m, 2H); 7.40-7.46 (m, 1H); 7.59 (s, 1H); 7.72 (bd, 1H).
  • According to the same procedure, the following compound can be obtained:
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester.
    EXAMPLE 5 5-(2-Bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid; (V)
  • A 0.2 M solution of 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid ethyl ester (1.77 g; 5.04 mM) in 1/1 v/v methanol/water is added with NaOH (605 mg; 15.12 mM). The mixture is kept at room temperature for about 15 hours, then acidified with KHSO4, extracted with ethyl acetate, dried over Na2SO4, filtered and evaporated under reduced pressure, thereby obtaining 1.42 g of 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid, as a white-pale yellow solid which is used in the subsequent reaction without further purification. (Yield: 87%).
  • According to the same procedure, the following compound can be obtained:
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid.
    EXAMPLE 6 5-(2-Bromophenyl)-1-isobutyl-1H-imidazole-4-carboxamide; (III)
  • A 0.2 M solution of 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxylic acid (1.42 g; 4.4 mM) in anhydrous THF is added drop by drop, at 0° C., with oxalyl chloride (376111; 4.4 mM), then left to react at room temperature for about one hour, thus obtaining 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-chlorocarbonyl. The mixture is then added drop by drop with 3 ml of conc. NH3 and reacted for one hour, then extracted with ethyl acetate, dried over Na2SO4, filtered and evaporated under reduced pressure, thereby obtaining 1.14 g of 5-(2-bromophenyl)-1-isobutyl-1H-imidazole-4-carboxamide which is used directly in the subsequent reaction. (Yield: 80.5%).
  • 1H-NMR (CDCl3) δ 0.79 (d, 3H); 0.84 (d, 3H); 1.82 (m, 1H); 3.48 (q, 1H); 3.66 (q, 1H); 5.30-5.37 (bs, 1H); 7.11-7.18 (bs, 1H); 7.32-7.38 (m, 2H); 7.41-7.46 (m, 1H); 7.65 (bs, 1H); 7.69-7.73 (m, 1H).
  • According to the same procedure, the following compound can be obtained:
    • 5-(2-chlorophenyl)-1-isobutyl-1H-imidazole-4-carboxamide.
    EXAMPLE 7 1-Isobutyl-1,5-dihydro-imidazo[4,5-a]quinoline-4-one; (II)
  • 5-(2-Bromophenyl)-1-isobutyl-1H-imidazole-4-carboxamide (1.14 g; 3.54 mM), CuI (134.8 mg) and potassium carbonate (978 mg; 7.08 mM) are placed in a round-bottom flask under N2 for about 15 minutes, then 35.4 ml of anhydrous toluene and N,N′-dimethylethylenediamine (45 μl) are added and the mixture is refluxed at 110° C. under nitrogen atmosphere. After 48 h the solvent is evaporated off under reduced pressure and the mixture is purified by flash chromatography, eluting with ethyl acetate/methanol in 75/25 v/v ratio, thereby obtaining 307 mg of 1-isobutyl-1,5-dihydro-imidazo[4,5-a]quinoline-4-one. (Yield: 36%)
  • 1H-NMR (CDCl3) δ 0.91 (d, 6H); 2.12 (m, 1H); 4.38 (d, 2H); 7.25-7.31 (m, 1H); 7.43-7.50 (m, 2H); 7.95 (d, 1H); 8.14 (bs, 1H); 11.60 (bs, 1H).
    • EXAMPLE 8 1-Isobutyl-4-chloro-1H-imidazo[4,5-c]quinoline; (I)
  • A solution of 1-isobutyl-1,5-dihydro-imidazo[4,5-a]quinoline-4-one (307 mg; 1.18 mM) in POCl3 (1 ml) is refluxed for about one hour 30 min., then quenched with ice-water, alkalinised by dropwise addition of conc. NH4OH and extracted with ethyl acetate. The organic phase is dried over Na2SO4, filtered and evaporated under reduced pressure. The crude is purified by flash chromatography, eluting with ethyl acetate, thereby obtaining 90 mg of 1-isobutyl-4-chloro-1H-imidazo[4,5-c]quinoline. (Yield: 30%).
  • 1H-NMR (CDCl3) δ 1.08 (d, 6H); 2.37-2.43 (m, 1H); 4.41 (d, 2H); 7.73 (ddd, 1H, J1=7.0 J2=8.5 J3=1.5 Hz); 7.68 (ddd, 1H, J3=7.0 J2=8.3 J3=1.3 Hz); 8.09-8.13 (m, 2H); 8.22-8.27 (m, 1H).

Claims (1)

1. 1-Isobutyl-1,5-dihydro-imidazo[4,5-a]quinoline-4-one, tautomeric forms and isomers thereof.
US11/872,895 2003-11-04 2007-10-16 Process for the preparation of imiquimod and intermediates thereof Abandoned US20080161573A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/872,895 US20080161573A1 (en) 2003-11-04 2007-10-16 Process for the preparation of imiquimod and intermediates thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2003A002121 2003-11-04
IT002121A ITMI20032121A1 (en) 2003-11-04 2003-11-04 PROCEDURE FOR THE PREPARATION OF IMIQUIMOD AND ITS INTERMEDIATES
US10/979,209 US7301027B2 (en) 2003-11-04 2004-11-03 Process for the preparation of Imiquimod and intermediates thereof
US11/872,895 US20080161573A1 (en) 2003-11-04 2007-10-16 Process for the preparation of imiquimod and intermediates thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/979,209 Division US7301027B2 (en) 2003-11-04 2004-11-03 Process for the preparation of Imiquimod and intermediates thereof

Publications (1)

Publication Number Publication Date
US20080161573A1 true US20080161573A1 (en) 2008-07-03

Family

ID=34430750

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/979,209 Expired - Fee Related US7301027B2 (en) 2003-11-04 2004-11-03 Process for the preparation of Imiquimod and intermediates thereof
US11/872,895 Abandoned US20080161573A1 (en) 2003-11-04 2007-10-16 Process for the preparation of imiquimod and intermediates thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/979,209 Expired - Fee Related US7301027B2 (en) 2003-11-04 2004-11-03 Process for the preparation of Imiquimod and intermediates thereof

Country Status (3)

Country Link
US (2) US7301027B2 (en)
EP (1) EP1529781A1 (en)
IT (1) ITMI20032121A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3950687A1 (en) 2020-08-07 2022-02-09 PHV Pharma Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538057A (en) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー Ether-substituted imidazopyridine
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
MXPA06001669A (en) 2003-08-12 2006-04-28 3M Innovative Properties Co Oxime substituted imidazo-containing compounds.
EP2939693A1 (en) * 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
KR101494056B1 (en) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005048933A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CN1906192A (en) 2003-11-14 2007-01-31 3M创新有限公司 Hydroxylamine substituted imidazo ring compounds
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005076783A2 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2552101A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2005283085B2 (en) * 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
JP5209312B2 (en) * 2004-09-02 2013-06-12 スリーエム イノベイティブ プロパティズ カンパニー 1-alkoxy 1H-imidazo ring systems and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
JP2008515928A (en) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Adjuvants for DNA vaccines
AU2005321912B2 (en) * 2004-12-30 2012-04-05 3M Innovative Properties Company Treatment for cutaneous metastases
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP5313502B2 (en) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008530022A (en) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド Aqueous gel formulation containing immune response modifier
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (en) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
EP2009002A1 (en) * 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
DK2310044T3 (en) * 2008-06-16 2016-12-12 Mediolanum Farm S P A Antitumor IMMUNOTHERAPY
JP2010150200A (en) * 2008-12-25 2010-07-08 Tosoh Corp Imidazole compound and method for producing the same
LT2606047T (en) 2010-08-17 2017-04-10 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
CN112546238A (en) 2014-09-01 2021-03-26 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698348A (en) * 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
JP2003518125A (en) * 1999-12-22 2003-06-03 イーライ・リリー・アンド・カンパニー Methods and compounds for inhibiting MRP1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698348A (en) * 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3950687A1 (en) 2020-08-07 2022-02-09 PHV Pharma Industrial method for synthesising imiquimod from quinoline-2,4-diol applicable to the pharmaceutical use thereof
FR3113287A1 (en) 2020-08-07 2022-02-11 Phv Pharma Industrial process for the synthesis of imiquimod from quinoline-2,4-diol applicable to its pharmaceutical use

Also Published As

Publication number Publication date
US20050165236A1 (en) 2005-07-28
US7301027B2 (en) 2007-11-27
EP1529781A1 (en) 2005-05-11
ITMI20032121A1 (en) 2005-05-05

Similar Documents

Publication Publication Date Title
US7301027B2 (en) Process for the preparation of Imiquimod and intermediates thereof
KR102421025B1 (en) New Trityl Protective Agent
US20180201601A1 (en) Process for preparing apalutamide
TWI695824B (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
JP5816262B2 (en) Method for producing dithiintetracarboximides
JP4528123B2 (en) Process for the production of nitrooxy derivatives of naproxen
Zhang et al. Copper (I)‐Catalyzed Intramolecular N‐N Coupling of Cyclopropyl O‐Acyl Ketoximes: Synthesis of Spiro‐fused Pyrazolin‐5‐ones
JP4041881B2 (en) Novel N-thio-substituted heterocyclic compound and method for producing the same
Elmuradov et al. Directions of reactions of 6-amino-,-acetylamino-, and-benzoylaminodeoxyvasicinones with aldehydes
TWI781128B (en) Processes for the preparation of pesticidal compounds
EP3562808B1 (en) Processes for the preparation of pesticidal compounds
JP4853911B2 (en) Method for producing isothiazolopyridin-3-one compound
JP4238361B2 (en) Method for producing N-sulfenylamino acid ester compound
US10112901B2 (en) Method for preparing dabigatran etexilate intermediate, and intermediate compound
CN105669678A (en) Phthalazinopyrrole compound and preparation method thereof
JP4729742B2 (en) Method for producing isothiazolopyridine compound
JP2020537680A (en) Process for producing herbicidal pyridadinone compounds
JP4635178B2 (en) Novel N-sulfenyl substituted heterocyclic compound and method for producing the same
RU2290398C2 (en) Method for preparing 5-amino-3-n-r1-amino-1-r-1,2,4-triazole
JP4214229B2 (en) Novel N-sulfenylamino acid ester compound and method for producing the same
Richards New Methods for the Synthesis of Novel Triazoles as Ligands and Potential Drugs
JP4982790B2 (en) Method for producing isothiazolopyridin-3-one compound
JP4729738B2 (en) Novel N-sulfenylpyrrole compound and method for producing the same
WO2005063678A1 (en) Process for producing phenylacetic acid derivative
JP4690733B2 (en) Method for producing 3-hydroxypyrazole-1-carboxamide derivative

Legal Events

Date Code Title Description
AS Assignment

Owner name: DIPHARMA S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLOMBO, LINO;MARIOTTI, ENRICO;ALLEGRINI, PIETRO;AND OTHERS;REEL/FRAME:019968/0741;SIGNING DATES FROM 20041018 TO 20041021

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION